Health knowledge made personal
Join this community!
› Share page:
Search posts:

Tumor Markers in Ovarian Cancer

Posted May 31 2007 5:00pm

Description of Invention:
Ovarian cancer is one of the most common forms of neoplasia in women. Although advanced ovarian cancer has only a 20-30% survival rate, an estimated 90% of cases are effectively treated when detected early. However, few symptoms are associated with early ovarian cancer, and approximately 25% of ovarian cancer cases are diagnosed before it metastasizes. Utilizing SAGE analysis, a unique set of ovarian cancer biomarkers has been identified that are highly expressed in ovarian epithelial tumor cells in comparison to normal ovarian epithelial cells. A better knowledge of the mechanisms underlying ovarian tumorigenesis will likely result in the development of novel approaches for the diagnosis and therapy of this deadly disease.

  • Method to diagnose ovarian cancer
  • Methods to treat patients with compositions that inhibit ovarian biomarkers such as siRNA

Development Status:
The technology is currently in the pre-clinical stage of development.

Patrice J Morin (NIA)

Patent Status:
HHS, Reference No. E-138-2000/0
US, , Patent No. 7,279,294, Issued 09 Oct 2007
US, Application No. 11/895,326 filed 24 Aug 2007
US, Application No. 12/700,311 filed 04 Feb 2010

Relevant Publication:
  1. KJ Hewitt, R Agarwal, PJ Morin. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006 Jul 12;6:186. [ PubMed abs ]
  2. PJ Morin. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005 Nov 1;65(21):9603-9606. [ PubMed abs ]
  3. R Agarwal, T D'Souza, PJ Morin. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005 Aug 15;65(16):7378-7385. [ PubMed abs ]
  4. CD Hough, CA Sherman-Baust, ES Pizer, PJ Morin. Use of SAGE to study gene expression in ovarian cancer. American Association for Cancer Research, 9th Annual Meeting, April 10-14, 1999, Philadelphia, Pennsylvania.

Licensing Status:
Available for licensing.

Cancer - Diagnostics
Rare Diseases

For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-4633
Fax: 301-402-0220

Ref No: 213

Updated: 06/2007

Post a comment
Write a comment:

Related Searches